ストックスクリーナーアプリを入手
26.19
6.50%
-1.82
アフターアワーズ：
25.86
-0.33
-1.26%
前日終値:
$28.01
開ける：
$27.1
24時間の取引高:
18.45M
Relative Volume:
0.57
時価総額：
$6.06B
収益：
$2.35B
当期純損益:
$128.37M
株価収益率:
50.16
EPS:
0.5221
ネットキャッシュフロー:
$57.42M
1週間 パフォーマンス:
+0.15%
1か月 パフォーマンス:
-0.53%
6か月 パフォーマンス:
-33.19%
1年 パフォーマンス:
-50.37%
1日の値動き範囲:
$25.40
$27.89
1週間の範囲:
$25.40
$29.82
52週間の値動き範囲:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
26.19 | 6.48B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
15.60 | 48.82B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.12 | 39.63B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.19 | 40.09B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.44 | 33.34B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.87 | 23.25B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | 開始されました | JP Morgan | Overweight |
| 2026-03-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2026-03-10 | アップグレード | Citigroup | Sell → Neutral |
| 2026-03-09 | アップグレード | Needham | Hold → Buy |
| 2026-02-24 | ダウングレード | BTIG Research | Buy → Neutral |
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Hims & Hers Health Stock (HIMS) Opinions on Biotech Sector Momentum - Quiver Quantitative
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now? - Insider Monkey
Hims & Hers Health Options Spot-On: On June 1st, 185.47K Contracts Were Traded, With 1.08 Million Open Interest - Moomoo
Hims & Hers Health Options Spot-On: On June 3rd, 96,548 Contracts Were Traded, With 1.06 Million Open Interest - Moomoo
How Investors Are Reacting To Hims & Hers Health (HIMS) Hiring a Longevity-Focused Chief Medical Officer - simplywall.st
HIMS Stock On The Mend? New Testosterone Push Builds As GLP-1 Gold Rush Gets Crowded - Stocktwits
Hims & Hers Health Options Spot-On: On June 5th, 153.61K Contracts Were Traded, With 1.08 Million Open Interest - Moomoo
HIMS Stock Eyes 2-Week Green Streak: Analyst Sees Nearly 20% Upside On Multi-Year Opportunity In Peptides - Stocktwits
Hims CMO Appointment Highlights Longevity Focus And Raises Valuation Questions - Yahoo Finance
Hims & Hers Stock Closes Eucalyptus Deal With a $20 Billion Peptide Bet on Deck. Here’s What to Expect - TIKR.com
Hims & Hers expands UK footprint with Eucalyptus acquisition - Pharmacy Business
Great News: Wall Street Is Turning Bullish on This Troubled Telehealth Stock - The Globe and Mail
HIMS Stock Slides Overnight: CEO Sees Healthcare Potential In Anthropic's AI Leap As Lilly, WeightWatchers Turn Up The Heat - Stocktwits
HIMS News | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
HIMS Stock | Hims & Hers Health, Inc. Price, Quote, News & Analysis - TipRanks
Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims - Hims & Hers Newsroom
Price-Driven Insight from (HIMS) for Rule-Based Strategy - Stock Traders Daily
Hims & Hers Names Anant Vinjamoori Chief Medical Officer of Hims Brand - INDIA New England News
Hims & Hers Stock Jumps: What's Happening Today? - Benzinga
Hims & Hers Health Jumps 7.0% Amid Sector-Wide Rally - AlphaStreet
$Hims & Hers Health (HIMS.US)$ Never expect the rise on bad day and forgot to cancel my 1 week GTD[Hurt][Hurt][Hurt] - Moomoo
Why is Hims & Hers Health stock rallying today? By Investing.com - Investing.com Canada
Hims & Hers appoints Dr. Anant Vinjamoori as chief medical officer - Investing.com Canada
1 Growth Stock Set to Flourishand 2 We Ignore - The Globe and Mail
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
CCORF Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
HIMS Stock Slips Despite Early Eucalyptus Buyout Close: Analyst Sees 10% Downside On GLP-1 Profit Risks - Stocktwits
Most and least shorted mid- to mega-cap healthcare stocks at the end of May - Seeking Alpha
Canaccord reiterates Hims & Hers stock Buy rating on peptide growth - Investing.com
Taking A Fresh Look At Hims & Hers Health (HIMS) Valuation After Recent Share Price Swings - Yahoo Finance
Political Scrutiny Tests Hims And Hers GLP1 Weight Loss Growth Story - Yahoo Finance
Hims And Hers Expands Globally With Eucalyptus Deal And Valuation Gap - simplywall.st
HIMS stock slips despite early eucalyptus buyout close: Analyst sees 10% downside on GLP-1 profit risks - MSN
Hims & Hers Health Options Spot-On: On June 2nd, 101.18K Contracts Were Traded, With 1.04 Million Open Interest - Moomoo
Hims & Hers Health (Derivatives) price today, HIMS to USD live price, marketcap and chart - CoinMarketCap
EXCLUSIVE: Sen. Jim Banks wants FDA and FTC to investigate whether Hims & Hers is undermining TrumpRx - Washington Reporter
HIMS: 2030 targets hinge on global expansion, AI-driven care, and integrated specialty growth - TradingView
Hims & Hers Expands With Eucalyptus Acquisition - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Hims & Hers Health, Inc. completed the acquisition of EUC Management Pty Ltd. - marketscreener.com
Leerink maintains Hims and Hers stock rating on acquisition timing - Investing.com
Sector Update: Healthcare Stocks Down Premarket Tuesday - Moomoo
HIMS Expands Global Reach with Eucalyptus Acquisition - GuruFocus
Hims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese Market - GuruFocus
Hims & Hers completes acquisition of Eucalyptus in Australia - Investing.com Australia
Hims & Hers Closes Eucalyptus Deal, Expands Global Platform - TipRanks
Hims & Hers Amends Revolving Credit Agreement With JPMorgan to Support Eucalyptus Deal - TradingView
Hims And Hers Health Expands With Eucalyptus Acquisition And Global Growth Prospects - Yahoo Finance
Hims & Hers (NYSE: HIMS) expands with Eucalyptus deal and 2030 growth targets - Stock Titan
Hims & Hers completes acquisition of Eucalyptus, enters Japan By Investing.com - Investing.com Australia
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
Hims Hers Health Inc (HIMS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Okupe Oluyemi | Chief Financial Officer |
May 18 '26 |
Option Exercise |
5.01 |
7,950 |
39,830 |
270,904 |
| Okupe Oluyemi | Chief Financial Officer |
May 18 '26 |
Sale |
23.64 |
7,950 |
187,916 |
262,954 |
| Boughton Soleil | Chief Legal Officer |
Apr 20 '26 |
Sale |
30.00 |
9,463 |
283,890 |
299,368 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 20 '26 |
Option Exercise |
8.65 |
12,553 |
108,531 |
282,599 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 20 '26 |
Sale |
29.96 |
19,645 |
588,615 |
262,954 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 17 '26 |
Option Exercise |
5.01 |
6,184 |
30,982 |
288,051 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 16 '26 |
Sale |
25.90 |
36,922 |
956,147 |
281,867 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 17 '26 |
Sale |
27.83 |
18,005 |
501,158 |
270,046 |
9.79%
0.00%
大文字化:
|
ボリューム (24 時間):